Evidence map›Paper›PMID 42844558›Full record

ArticleDermatology and therapy2026

Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials.

Andrew E Pink, Zakiya P Rice, Melinda J Gooderham, Fang Wang, Andreas Wollenberg, Pinaki Biswas, Gary Chan, Justine Alderfer, Melissa Watkins

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03422822 phase3completednot on this map

A phase 3 multi-center, long-term extension study investigating the efficacy and safety of abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with moderate to severe atopic dermatitis

TypeinterventionalSponsorPfizerRan2018 to 2025Enrolled3,166ConditionsDermatitis, AtopicArmsAbrocitinib 100 mg, Abrocitinib 200 mg, Placebo
NCT03720470 phase3completednot on this map

A phase 3 randomized, double-blind, double-dummy, placebo-controlled, parallel group, multi-center study investigating the efficacy and safety of pf-04965842 and dupilumab in comparison with placebo in adult subjects on background topical therapy, with moderate to severe atopic dermatitis

TypeinterventionalSponsorPfizerRan2018 to 2020Enrolled838ConditionsDermatitis, Dermatitis, Atopic, Eczema, Skin DiseasesArmsPF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrew E PinkSt John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, Floor 2, Counting House, Guy's Hospital, London, SE1 9RT, UK. andrew.pink3@nhs.net.
Zakiya P RiceDermatology Associates of Georgia, Atlanta, GA, USA.
Melinda J GooderhamSKiN Centre for Dermatology, Peterborough, ON, Canada.
Fang WangDermatology Hospital, Southern Medical University, Guangzhou, China.
Andreas WollenbergUniversity Hospital Augsburg, Augsburg, Germany.
Pinaki BiswasPfizer Inc., New York, NY, USA.
Gary ChanPfizer Inc., Groton, CT, USA.
Justine AlderferPfizer Inc., Collegeville, PA, USA.
Melissa WatkinsPfizer Inc., New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBaseline severity of atopic dermatitis (AD) may influence treatment response. The objective of this analysis was to assess short- and long-term abrocitinib efficacy and safety by baseline AD severity.

methodsA post-hoc analysis of patients (aged ≥ 12 years) with moderate-to-severe AD receiving abrocitinib 100 mg or 200 mg or placebo in two studies-JADE COMPARE (ClinicalTrials.gov ID: NCT03720470) and JADE EXTEND (NCT03422822)-was performed. Baseline severity was assessed by several measures, including the Investigator's Global Assessment (IGA) and the Eczema Area and Severity Index (EASI). Efficacy and safety endpoints were stratified by baseline severity.

resultsHigher proportions of patients with moderate or severe baseline AD achieved IGA score 0/1 (clear/almost clear) with abrocitinib at week 16 (moderate: 40.8% [100 mg], 50.0% [200 mg]; severe: 19.1% [100 mg], 43.2% [200 mg]) versus placebo (moderate: 18.0%; severe: 2.8%). At week 112, IGA 0/1 was achieved by high proportions of patients receiving abrocitinib with moderate (60.2% [100 mg], 64.3% [200 mg]) or severe (38.6% [100 mg], 54.5% [200 mg]) disease. Response rates were similar with other measures, including co-achievement of EASI-90 (90% improvement from baseline score) and Peak Pruritus Numerical Rating Scale 0/1 (no itch/mild itch). There were no new safety signals.

conclusionAbrocitinib demonstrated early and sustained improvement in skin clearance and itch through week 112 in adult and adolescent patients, and sustained responses were observed in patients in the moderate and severe baseline AD subgroups. CLINICAL TRIALS REGISTRATION: This study was a pooled analysis of data from the phase 3 JADE COMPARE (NCT03720470) and JADE EXTEND (NCT03422822) trials.

Indexed as

AbrocitinibAtopic dermatitisDisease severityItchJanus kinase inhibitorPruritusSkin clearance

Identifiers

PMID42844558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.